REFERENCES
1. Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis 2017;9:448-51.
4. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell 2017;168:670-91.
5. Mahjour F, Dambal V, Shrestha N, et al. Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB. Oncogenesis 2019;8:34.
6. Zhang L, Meng X, Zhu XW, et al. Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications. Mol Cancer 2019;18:102.
7. Saraswat N, Everett B, Pillay R, Prabhu N, George A. Knowledge, attitudes and practices of general medical practitioners in developed countries regarding oral cancer: an integrative review. Fam Pract 2020;37:592-605.
10. Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg 2011;10:132-7.
12. Speight PM. Update on oral epithelial dysplasia and progression to cancer. Head Neck Pathol 2007;1:61-6.
13. Ye Y, Lippman SM, Lee JJ, et al. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer 2008;113:2488-95.
14. Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer 2019;18:63.
15. Shih JW, Chiang WF, Wu ATH, et al. Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1alpha co-activator driving oral cancer progression. Nat Commun 2017;8:15874.
16. Rao CV. Immunomodulatory effects of Momordica charantia extract in the prevention of oral cancer. Cancer Prev Res (Phila) 2018;11:185-6.
17. Burgy M, Barthélémy P, Lefevre F, et al. Cetuximab-carboplatin-5-fluorouracil regimen in elderly patients with recurrent or metastatic head and neck squamous-cell carcinoma: a French retrospective survey. Oncology 2017;93:11-7.
18. Nishiyama K, Maruyama R, Niinuma T, et al. Screening for long noncoding RNAs associated with oral squamous cell carcinoma reveals the potentially oncogenic actions of DLEU1. Cell Death Dis 2018;9:826.
19. Tan DSW, Chong FT, Leong HS, et al. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nat Med 2017;23:1167-75.
20. Oyebode O, Kandala NB, Chilton PJ, Lilford RJ. Use of traditional medicine in middle-income countries: a WHO-SAGE study. Health Policy Plan 2016;31:984-91.
21. Safarzadeh E, Sandoghchian Shotorbani S, Baradaran B. Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull 2014;4:421-7.
23. Jia S, Shen M, Zhang F, Xie J. Recent Advances in Momordica charantia: Functional Components and Biological Activities. Int J Mol Sci 2017;18:2555.
24. Dandawate PR, Subramaniam D, Padhye SB, Anant S. Bitter melon: a panacea for inflammation and cancer. Chin J Nat Med 2016;14:81-100.
25. Raina K, Kumar D, Agarwal R. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy. Semin Cancer Biol 2016;40-41:116-29.
26. Sur S, Ray RB. Bitter melon (Momordica charantia), a nutraceutical approach for cancer prevention and therapy. Cancers (Basel) 2020;12:2064.
27. Fang EF, Froetscher L, Scheibye-Knudsen M, Bohr VA, Wong JH, Ng TB. Emerging antitumor activities of the bitter melon (Momordica charantia). Curr Protein Pept Sci 2019;20:296-301.
28. Upadhyay A, Agrahari P, Singh D. A Review on Salient Pharmacological Features of Momordica charantia. International J of Pharmacology 2015;11:405-13.
29. Rajamoorthi A, Shrivastava S, Steele R, et al. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling. PLoS One 2013;8:e78006.
30. Bhattacharya S, Muhammad N, Steele R, Peng G, Ray RB. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth. Oncotarget 2016;7:33202-9.
31. Duarte S, Loubat A, Momier D, et al. Isolation of head and neck squamous carcinoma cancer stem-like cells in a syngeneic mouse model and analysis of hypoxia effect. Oncol Rep 2012;28:1057-62.
32. Sominski DD, Rafferty P, Brosnan K, et al. Development of a squamous cell carcinoma mouse model for immunotoxicity testing. J Immunotoxicol 2016;13:226-34.
33. Wang Z, Wu VH, Allevato MM, et al. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nat Commun 2019;10:5546.
34. Li H, Ngan HL, Liu Y, et al. Comprehensive exome analysis of immunocompetent metastatic head and neck cancer models reveals patient relevant landscapes. Cancers (Basel) 2020;12:2935.
35. Sur S, Steele R, Aurora R, Varvares M, Schwetye KE, Ray RB. Bitter melon prevents the development of 4-NQO-induced oral squamous cell carcinoma in an immunocompetent mouse model by modulating immune signaling. Cancer Prev Res (Phila) 2018;11:191-202.
36. Hsiao PC, Liaw CC, Hwang SY, et al. Antiproliferative and hypoglycemic cucurbitane-type glycosides from the fruits of Momordica charantia. J Agric Food Chem 2013;61:2979-86.
37. Liaw CC, Huang HC, Hsiao PC, et al. 5beta,19-epoxycucurbitane triterpenoids from Momordica charantia and their anti-inflammatory and cytotoxic activity. Planta Med 2015;81:62-70.
38. Todd R, Hinds PW, Munger K, et al. Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med 2002;13:51-61.
39. Visconti R, Della Monica R, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. J Exp Clin Cancer Res 2016;35:153.
40. Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 2010;70:1925-31.
41. Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res (Phila) 2011;4:2122-30.
43. Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 2018;17:45.
44. Arnold L, Enders J, Thomas SM. Activated HGF-c-Met Axis in Head and Neck Cancer. Cancers (Basel) 2017;9:169.
45. Chen Q, Kang J, Fu C. The independence of and associations among apoptosis, autophagy, and necrosis. Signal Transduct Target Ther 2018;3:18.
46. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res 2002;8:2024-34.
47. Sur S, Nakanishi H, Flaveny C, et al. Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract. Cell Commun Signal 2019;17:131.
48. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. J Gen Physiol 1927;8:519-30.
49. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016;5:e189.
50. Bhattacharya S, Muhammad N, Steele R, Kornbluth J, Ray RB. Bitter melon enhances natural killer-mediated toxicity against head and neck cancer cells. Cancer Prev Res (Phila) 2017;10:337-44.
51. Fang WY, Chen YW, Hsiao JR, et al. Elevated S100A9 expression in tumor stroma functions as an early recurrence marker for early-stage oral cancer patients through increased tumor cell invasion, angiogenesis, macrophage recruitment and interleukin-6 production. Oncotarget 2015;6:28401-24.
52. Markowitz J, Carson WE 3rd. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta 2013;1835:100-9.
53. Srikrishna G. S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun 2012;4:31-40.
54. Mark R, Bermejo JL, Bierhaus A, Plinkert PK, Angel P, Hess J. The receptor for advanced glycation end products is dispensable in a mouse model of oral and esophageal carcinogenesis. Histol Histopathol 2013;28:1585-94.
55. Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016;4:173.
